Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654972 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT07654972 is a Phase 1 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 108 participants.
The verdict
NCT07654972, a Phase 1 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).
Interventions
- DRUG Placebo
- DRUG LY4174794
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07654972
The ClinicalTrials.gov registry entry for NCT07654972 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07654972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07654972 about?
NCT07654972 is a clinical study titled "A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy". The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Particip...
What is the current status of trial NCT07654972?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2026-06. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07654972?
The interventions under investigation include: Placebo (DRUG), LY4174794 (DRUG).
Who is sponsoring clinical trial NCT07654972?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.